Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Kim JM, Bhatt DL, Dagogo-Jack S, Cherney DZI, Cosentino F, McGuire DK, Pratley RE, Liu CC, Cater NB, Frederich R, Mancuso JP, Cannon CP. Kim JM, et al. Diabetes Obes Metab. 2023 May;25(5):1398-1402. doi: 10.1111/dom.14965. Epub 2023 Feb 14. Diabetes Obes Metab. 2023. PMID: 36594154 No abstract available.
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
Corbin KD, Dagogo-Jack S, Cannon CP, Cherney DZI, Cosentino F, Frederich R, Liu J, Pong A, Lin J, Cater NB, Pratley RE. Corbin KD, et al. Diabetes Obes Metab. 2023 Mar;25(3):758-766. doi: 10.1111/dom.14923. Epub 2022 Dec 26. Diabetes Obes Metab. 2023. PMID: 36394384 Clinical Trial.
Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, Lawrence D, Jones PLS, Liu J, Adamsons I, Dagogo-Jack S. Pratley RE, et al. Lancet Healthy Longev. 2023 Apr;4(4):e143-e154. doi: 10.1016/S2666-7568(23)00032-6. Lancet Healthy Longev. 2023. PMID: 37003273 Free article. Clinical Trial.
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial.
Cherney DZI, Cosentino F, McGuire DK, Kolkailah AA, Dagogo-Jack S, Pratley RE, Frederich R, Maldonado M, Liu CC, Cannon CP; VERTIS CV Investigators. Cherney DZI, et al. Kidney Int Rep. 2023 Jan 20;8(4):746-753. doi: 10.1016/j.ekir.2023.01.011. eCollection 2023 Apr. Kidney Int Rep. 2023. PMID: 37069970 Free PMC article.
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Odutayo A, Cosentino F, Pratley RE, Dagogo-Jack S, McGuire DK, Frederich R, Fu W, Cannon CP, Cherney DZI; VERTIS CV Investigators. Odutayo A, et al. Among authors: dagogo jack s. Diabetes Obes Metab. 2024 Aug;26(8):3478-3481. doi: 10.1111/dom.15687. Epub 2024 Jun 5. Diabetes Obes Metab. 2024. PMID: 38840474 Clinical Trial. No abstract available.
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
Sridhar VS, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Cater NB, Noyes Essex M, Mancuso JP, Zhao Y, Cherney DZI. Sridhar VS, et al. Among authors: dagogo jack s. Diabetes Obes Metab. 2024 Nov;26(11):5336-5346. doi: 10.1111/dom.15895. Epub 2024 Sep 2. Diabetes Obes Metab. 2024. PMID: 39219437 Clinical Trial.
Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP).
Li JH, Perry JA, Jablonski KA, Srinivasan S, Chen L, Todd JN, Harden M, Mercader JM, Pan Q, Dawed AY, Yee SW, Pearson ER, Giacomini KM, Giri A, Hung AM, Xiao S, Williams LK, Franks PW, Hanson RL, Kahn SE, Knowler WC, Pollin TI, Florez JC; Diabetes Prevention Program Research Group:. Li JH, et al. Diabetes. 2023 Aug 1;72(8):1161-1172. doi: 10.2337/db22-0702. Diabetes. 2023. PMID: 36525397 Free PMC article.
308 results